cannabinor

Cannabinor is a synthetic small molecule that acts as a potent and selective agonist of the cannabinoid CB2 receptor. It is classified as a "nonclassical" cannabinoid with a chemical structure similar to cannabidiol but exhibits over 300-fold selectivity for CB2 versus CB1 receptors. Cannabinor was developed primarily as an analgesic for pain management—especially neuropathic pain—and showed promising results in preclinical animal models. However, it failed to demonstrate efficacy in Phase IIb human clinical trials and its development was discontinued. The drug was originally developed by Pharmos Corporation[1][2][3][5][10].

Other names

cannabinorPRS-211,375PRS-211375PRS211375PRS 211375PRS 375PRS375PRS-375